放射科医生对T2-FLAIR错配征的采用情况:我们做得如何?
这项回顾性队列研究纳入2017至2022年确诊的251例IDH突变型星形细胞瘤患者,分析286次术前MRI。经典T2-FLAIR错配征占22.3%,部分错配占29.8%,无错配占47.8%;影像报告中经典错配征报告率总体仅21.6%,专科癌症中心为43.3%,高于其他医院类别的0%-10.3%,且随年份呈统计学显著上升趋势。
要点
- 经典T2-FLAIR错配征在IDH突变型1p/19q非共缺失胶质瘤中占22.3%,部分错配占29.8%。
- 影像报告对经典错配征的报告率总体仅21.6%,专科癌症中心43.3%高于其他医院类别0%-10.3%。
- 有神经放射学专科培训的医生报告率25.0%,显著高于无培训者的0.0%。
核心结论
- T2-FLAIR错配征未被充分利用,尤其在非专科癌症中心机构;提高对该征象的认识可能改善IDH突变型星形细胞瘤的术前诊断,且经典错配征虽在低级别IDH突变型胶质瘤中更常见,在高级别肿瘤中仍有意义。
研究设计与样本
- 来自一家癌症转诊中心的回顾性队列研究,纳入2017至2022年确诊的251例IDH突变型星形细胞瘤患者,依据WHO 2021诊断标准审核病理报告;由2名神经放射学家分析286次术前MRI的错配与强化状态,并评估MRI报告对错配状态的报告频率及报告医生的神经放射学专科培训状态。
关键影像表现/征象
- 286次术前MRI中经典T2-FLAIR错配占22.3%,部分错配占29.8%,无错配占47.8%。
- 错配状态在WHO 2级与4级间显著不同,但在2级与3级间无显著差异。
- 男性与更高级别显著相关。
诊断标准与关键数值
- 经典T2-FLAIR错配征报告率总体为21.6%,专科癌症中心类别为43.3%,其他医院类别为0%-10.3%。
- 有神经放射学专科培训的医生报告率为25.0%,无培训者为0.0%,两者差异显著。
- 报告率随年份呈统计学显著上升趋势。
临床应用与阅片要点
- 影像报告中经典T2-FLAIR错配征报告率总体偏低(21.6%),提示日常报告中对IDH突变型星形细胞瘤的这一术前诊断征象利用不足。
- 专科癌症中心报告率(43.3%)高于其他医院类别(0%-10.3%),有神经放射学专科培训者报告率(25.0%)高于无培训者(0.0%)。
- 作者认为提高对T2-FLAIR错配征的认识可能改善IDH突变型星形细胞瘤的术前诊断。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: The classic T2-FLAIR mismatch sign is a highly specific MRI feature that can aid in preoperative diagnosis of isocitrate dehydrogenase (IDH)-mutant 1p/19q noncodeleted gliomas and affect surgical planning. This study aimed to assess the real-world utilization of the T2-FLAIR mismatch sign in clinical practice, and to explore the frequencies of classic- and partial T2-FLAIR mismatch within the IDH-mutant 1p/19q noncodeleted glioma population stratified by tumor grade.
MATERIALS AND METHODS: This retrospective cohort study from a dedicated cancer referral center included 251 patients with IDH-mutant astrocytoma diagnosed between 2017 and 2022. Pathology reports were reviewed for eligibility for the World Health Organization (WHO) 2021 diagnostic criteria. Preoperative MR imaging studies were analyzed by 2 neuroradiologists for the mismatch and enhancement status. MRI reports were assessed for mismatch status reporting frequency, and neuroradiology fellowship status of the dictating radiologist.
RESULTS: Two hundred eighty-six preoperative MRIs (212 from outside facilities and 74 in-house) were available from 251 patients with 251 tumors. Of these, 22.3% exhibited classic T2-FLAIR mismatch, 29.8% partial mismatch, and 47.8% no mismatch. Mismatch status significantly differed between WHO grades 2 and 4, but not between grades 2 and 3. Male sex was significantly associated with higher grade. Radiologist reporting rates for the classic mismatch sign were low overall (21.6%), but higher for the dedicated cancer center category (43.3%) compared with other hospital categories (0%-10.3%). The reporting rate was also significantly higher for radiologists with neuroradiology fellowship training compared with those without (25.0% versus 0.0%). A statistically significant upward trend in the reporting rate was observed over the years.
CONCLUSIONS: The T2-FLAIR mismatch sign is underutilized, particularly in institutions that are not specialized cancer centers. Raising awareness of the T2-FLAIR mismatch sign could enhance preoperative diagnosis of IDH-mutant astrocytoma. Additionally, while the classic mismatch sign is more common in lower-grade IDH-mutant gliomas, it remains relevant in higher-grade tumors.
引用
- Ucisik FE, Khanpara S, Ozkara BB, et al. Adoption of the T2-FLAIR Mismatch Sign among Radiologists: How Well Are We Doing? AJNR Am J Neuroradiol. 2025. PMID: 40210459. doi:10.3174/ajnr.A8783
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。